Turnstone lays off 60% of staff, shakes up C-suite to keep cancer cell therapy on track

Turnstone Biologics is reducing its headcount by 60% and shaking up its C-suite in order to keep the cash flowing to its sole clinical-stage candidate.

The biotech already narrowed the focus of the selected tumor-infiltrating lymphocyte (TIL) therapy in August to colorectal cancer, head and neck cancer and uveal melanoma, deprioritizing its work in cutaneous melanoma and breast cancer.